1. Home
  2. OLP vs MLYS Comparison

OLP vs MLYS Comparison

Compare OLP & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo One Liberty Properties Inc.

OLP

One Liberty Properties Inc.

HOLD

Current Price

$21.67

Market Cap

508.4M

Sector

Real Estate

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$27.06

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLP
MLYS
Founded
1982
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
508.4M
1.9B
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
OLP
MLYS
Price
$21.67
$27.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$27.50
$48.67
AVG Volume (30 Days)
71.5K
1.2M
Earning Date
03-05-2026
03-12-2026
Dividend Yield
8.32%
N/A
EPS Growth
N/A
37.43
EPS
1.15
N/A
Revenue
$82,740,000.00
N/A
Revenue This Year
$7.87
N/A
Revenue Next Year
$4.40
N/A
P/E Ratio
$18.81
N/A
Revenue Growth
1.02
N/A
52 Week Low
$19.62
$10.44
52 Week High
$26.63
$47.65

Technical Indicators

Market Signals
Indicator
OLP
MLYS
Relative Strength Index (RSI) 37.22 54.29
Support Level $20.09 $26.85
Resistance Level $23.38 $30.53
Average True Range (ATR) 0.51 1.50
MACD -0.17 0.26
Stochastic Oscillator 20.72 76.32

Price Performance

Historical Comparison
OLP
MLYS

About OLP One Liberty Properties Inc.

One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: